
Medpace (MEDP) 주식
헬스케어 섹터 기업. 9월 2026 기준 Medpace의 주가, 사업 개요, 알아두어야 할 핵심 정보를 정리했습니다.
Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company's drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company's operations are principally based in North America, Europe, and Asia.
6개월 성장 성과
주가 성과 요약
애널리스트 평가
Analysts suggest keeping MEDPACE's stock as is, with a target price indicating potential decline.
재무 건전성
Medpace is performing well financially with strong revenue and cash flow, indicating good business health.
앱을 무료로 다운로드하고 더 많은 종목 보기
60초면 충분합니다.
왜 Nemo와 함께 투자해야 할까요?
수수료 무료
주식, ETF 등을 수수료 없이 거래하세요. 수익을 더 많이 지키세요.
신뢰할 수 있는 규제 기관 인가
2015년부터 Exinity Group의 일원으로, 전 세계 100만 명 이상의 고객에게 서비스를 제공합니다.